Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis
暂无分享,去创建一个
X. Montalban | L. Kappos | C. Polman | H. Hartung | D. Miller | G. Edan | C. Pohl | R. Sandbrink | N. Dotan | L. Spector | E. Fire | J. Yarden | C. Metzig | V. Lanius | S. Schwenke